Cerus (CERS) FDA Contract is Validation of INTERCEPT - Cowen
Tweet Send to a Friend
Cowen analyst Joshua Jennings reiterated an Outperform rating and $9.50 price target on Cerus (NASDAQ: CERS) after the company has ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


